Document: Pseudomonas aeruginosa-induced biofilm infection is difficult to treat and poses a significant threat to public health. Our previous study found a
new coumarin derivative LP4C which exerted potent in vitro and in vivo anti-biofilm activity against Pseudomonas aeruginosa; however, the underlying
molecular mechanism and drug-likeness of LP4C is unclear. In this study, we confirmed that LP4C could inhibit the biofilm in dose-dependent manner
without bactericidal activity. The transcriptomic profiling and RT-PCR result revealed that bacterial pyrimidine mediated the inhibitory activity of
LP4C. The cell viability was not affected in LP4C treatment groups with the concentration under 200 μg / mL, and no death or toxicity sign was
observed in mice treated by 20, 40 and 80 mg / kg LP4C during the three-week test period. NAME_1 test presented that LP4C had no effect on the bacterial
reverse mutation. In additional, pharmacokinetic results showed that LP4C was likely to have the orally bioavailable properties. Our data indicate
that LP4C is a possible lead compound for the development of new anti-biofilm infection agents against Pseudomonas aeruginosa...

Task: Extract all mentioned molecular interactions triples, then return in this format (drug name, target name, interaction mode).  keep it very short to-the-point. Add stress words which are capitalized. Limit those stress words for less than 15 times.
user